Bristol-Myers Squibb Company Ce(CELG-RI)Earnings, Financials & Key Ratios

CELG-RI•NYSE

$0.10

$204M mkt cap·0.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryLarge diversified branded pharma

AboutBristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.Show more

Revenue$48.19B-0.2%
EBITDA$19.24B-0.1%
Net Income$7.05B+178.8%
EPS (Diluted)3.46+178.5%
Gross Margin65.9%+16.0%
EBITDA Margin39.92%+0.1%
Operating Margin31.37%+56.9%
Net Margin14.64%+179.0%
ROE40.43%+203.6%
ROIC19.8%+59.6%
Debt/Equity2.65-15.3%
Interest Coverage7.99+342.0%

Technical→

CELG-RI Key Insights

Bristol-Myers Squibb Company Ce (CELG-RI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 26.7% free cash flow margin
✓Momentum leader: RS Rating 92 (top 8%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.0x book value

✗Weaknesses

✗High debt to equity ratio of 2.6x
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CELG-RI Price & Volume

Bristol-Myers Squibb Company Ce (CELG-RI) stock price & volume — 10-year historical chart

Loading chart...

CELG-RI Growth Metrics

Bristol-Myers Squibb Company Ce (CELG-RI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.27%

5 Years2.54%

3 Years1.45%

TTM1.78%

Profit CAGR

10 Years15.82%

5 Years-

3 Years3.69%

TTM34.25%

EPS CAGR

10 Years13.56%

5 Years-

3 Years5.46%

TTM33.57%

Return on Capital

10 Years14.31%

5 Years13.48%

3 Years15.68%

Last Year22.32%

CELG-RI Recent Earnings

Bristol-Myers Squibb Company Ce (CELG-RI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 2/9 qtrs (50%)●Beat Revenue 5/9 qtrs (100%)

Q2 2026Latest

Apr 30, 2026

EPS

$1.58

Est $1.42

+11.3%

Revenue

$11.5B

Est $10.9B

+5.1%

Q1 2026

Feb 5, 2026

EPS

$1.26

Est $1.23

+2.4%

Revenue

$12.5B

Est $12.3B

+1.8%

Q4 2025

Oct 30, 2025

EPS

$1.08

Est $1.52

-28.9%

Revenue

$12.2B

Est $11.9B

+3.1%

Q3 2025

Jul 31, 2025

EPS

—

Est $1.09

Revenue

$12.3B

Est $11.4B

+7.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.58vs $1.42+11.3%	$11.5Bvs $10.9B+5.1%
Q1 2026	Feb 5, 2026	$1.26vs $1.23+2.4%	$12.5Bvs $12.3B+1.8%
Q4 2025	Oct 30, 2025	$1.08vs $1.52-28.9%	$12.2Bvs $11.9B+3.1%
Q3 2025	Jul 31, 2025	—vs $1.09	$12.3Bvs $11.4B+7.2%

Based on last 9 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
MRKMerck & Co., Inc.Direct Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
PFEPfizer Inc.Direct Competitor	150.4B	26.44	19.44	-1.65%	11.83%	8.34%	6.03%	0.78
AZNAstraZeneca PLCDirect Competitor	280.97B	181.24	27.71	8.63%	17.19%	22.24%	4.19%	0.61
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
ABBVAbbVie Inc.Direct Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
GILDGilead Sciences, Inc.Product Competitor	166.32B	133.48	351.26	6.04%	28.9%	37.62%	6.2%	1.39
BIIBBiogen Inc.Product Competitor	27.92B	189.13	21.42	1.39%	13.92%	7.55%	7.34%	0.38

Compare CELG-RI vs Peers

Bristol-Myers Squibb Company Ce (CELG-RI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BMY

Most directly comparable listed peer for CELG-RI.

Scale Benchmark

vs LLY

Larger-name benchmark to compare CELG-RI against a more recognizable public peer.

Peer Set

Compare Top 5

vs BMY, MRK, PFE, AZN

CELG-RI Income Statement

Bristol-Myers Squibb Company Ce (CELG-RI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	20.78B	22.56B	26.14B	42.52B	46.38B	46.16B	45.01B	48.3B	48.19B	48.48B
Revenue Growth %	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%	-0.22%	1.78%
Cost of Goods Sold	6.07B	6.55B	8.08B	11.77B	9.94B	10.14B	10.69B	20.87B	16.44B	16B
COGS % of Revenue	29.2%	29.02%	30.9%	27.69%	21.43%	21.96%	23.76%	43.2%	34.1%	-
Gross Profit	14.71B▲ 0%	16.01B▲ 8.9%	18.07B▲ 12.8%	30.75B▲ 70.2%	36.45B▲ 18.5%	36.02B▼ 1.2%	34.31B▼ 4.7%	27.43B▼ 20.1%	31.76B▲ 15.8%	32.48B▲ 0%
Gross Margin %	70.8%	70.98%	69.1%	72.31%	78.57%	78.04%	76.24%	56.79%	65.9%	67%
Gross Profit Growth %	1.58%	8.86%	12.82%	70.17%	18.54%	-1.16%	-4.74%	-20.05%	15.77%	-
Operating Expenses	11.26B	10.9B	12.15B	28.57B	27.91B	26.92B	26.12B	17.77B	16.64B	17.11B
OpEx % of Revenue	54.2%	48.3%	46.49%	67.19%	60.17%	58.32%	58.03%	36.8%	34.53%	-
Selling, General & Admin	4.85B	4.55B	4.87B	7.66B	7.69B	7.81B	7.77B	7.87B	7.15B	7.18B
SG&A % of Revenue	23.34%	20.17%	18.63%	18.02%	16.58%	16.93%	17.27%	16.28%	14.83%	-
Research & Development	6.41B	6.34B	6.15B	11.14B	10.2B	9.51B	9.3B	11.16B	9.49B	9.49B
R&D % of Revenue	30.86%	28.12%	23.52%	26.21%	21.98%	20.6%	20.66%	23.1%	19.7%	-
Other Operating Expenses	0	0	1.14B	9.76B	10.02B	9.6B	9.05B	-1.25B	0	1000K
Operating Income	3.45B▲ 0%	5.12B▲ 48.3%	5.91B▲ 15.5%	2.18B▼ 63.2%	8.54B▲ 292.1%	9.1B▲ 6.6%	8.2B▼ 10.0%	9.66B▲ 17.9%	15.12B▲ 56.5%	15.37B▲ 0%
Operating Margin %	16.61%	22.69%	22.62%	5.12%	18.4%	19.72%	18.21%	20%	31.37%	31.7%
Operating Income Growth %	-23.99%	48.35%	15.53%	-63.18%	292.15%	6.64%	-9.98%	17.85%	56.52%	-
EBITDA	4.32B	5.82B	7.66B	12.56B	19.22B	19.38B	17.95B	19.26B	19.24B	18.46B
EBITDA Margin %	20.8%	25.8%	29.29%	29.53%	41.44%	41.99%	39.89%	39.87%	39.92%	38.07%
EBITDA Growth %	-16.32%	34.68%	31.58%	63.95%	53.09%	0.82%	-7.35%	7.26%	-0.1%	1.88%
D&A (Non-Cash Add-back)	872M	703M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B	4.12B	3.09B
EBIT	5.33B	6.15B	5.63B	-5.45B	9.43B	8.95B	9.61B	-6.43B	15.12B	15.37B
Net Interest Income	-196M	-183M	-656M	-1.42B	-1.33B	-1.23B	-1.17B	-1.95B	-1.3B	-1.26B
Interest Income	0	0	0	0	0	0	0	0	586M	552M
Interest Expense	196M	183M	656M	1.42B	1.33B	1.23B	1.17B	1.95B	1.89B	1.81B
Other Income/Expense	-108M	-426M	-938M	-9.05B	-439M	-1.39B	245M	-18.04B	-5.79B	-5.77B
Pretax Income	5.13B▲ 0%	6.01B▲ 17.1%	4.97B▼ 17.2%	-6.87B▼ 238.1%	8.1B▲ 217.9%	7.71B▼ 4.8%	8.44B▲ 9.4%	-8.38B▼ 199.3%	9.33B▲ 211.3%	9.6B▲ 0%
Pretax Margin %	24.7%	26.64%	19.03%	-16.16%	17.46%	16.71%	18.75%	-17.35%	19.36%	19.79%
Income Tax	4.16B	1.03B	1.51B	2.12B	1.08B	1.37B	400M	554M	2.27B	2.32B
Effective Tax Rate %	81%	17.15%	30.45%	-30.91%	13.39%	17.74%	4.74%	-6.61%	24.36%	24.22%
Net Income	1.01B▲ 0%	4.95B▲ 391.8%	3.44B▼ 30.6%	-9.02B▼ 362.1%	6.99B▲ 177.6%	6.33B▼ 9.5%	8.03B▲ 26.8%	-8.95B▼ 211.5%	7.05B▲ 178.8%	7.28B▲ 0%
Net Margin %	4.85%	21.95%	13.15%	-21.2%	15.08%	13.71%	17.83%	-18.53%	14.64%	15.01%
Net Income Growth %	-77.41%	391.76%	-30.55%	-362.14%	177.58%	-9.54%	26.84%	-211.5%	178.83%	34.25%
Net Income (Continuing)	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B	7.06B	7.27B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	106M	96M	100M	60M	60M	57M	55M	53M	33M	34M
EPS (Diluted)	0.61▲ 0%	3.03▲ 396.7%	2.01▼ 33.7%	-3.98▼ 298.0%	3.12▲ 178.4%	2.95▼ 5.4%	3.86▲ 30.8%	-4.41▼ 214.2%	3.46▲ 178.5%	3.55▲ 0%
EPS Growth %	-76.98%	396.72%	-33.66%	-298.01%	178.39%	-5.45%	30.85%	-214.25%	178.46%	33.57%
EPS (Basic)	0.61	3.03	2.02	-3.98	3.15	2.97	3.88	-4.41	3.47	-
Diluted Shares Outstanding	1.65B	1.64B	1.71B	2.26B	2.25B	2.15B	2.08B	2.03B	2.04B	2.05B
Basic Shares Outstanding	1.65B	1.63B	1.71B	2.26B	2.22B	2.13B	2.07B	2.03B	2.03B	2.04B
Dividend Payout Ratio	255.91%	52.77%	77.9%	-	62.85%	73.24%	59.12%	-	71.52%	-

CELG-RI Balance Sheet

Bristol-Myers Squibb Company Ce (CELG-RI) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	14.85B	8.88B	29.35B	30.19B	33.26B	27.27B	31.77B	29.78B	29.39B	27.21B
Cash & Short-Term Investments	6.81B	8.88B	12.35B	16.54B	17.22B	9.25B	12.28B	10.86B	10.67B	10.49B
Cash Only	5.42B	6.91B	12.35B	14.63B	13.98B	9.12B	11.46B	10.35B	10.21B	9.57B
Short-Term Investments	1.39B	1.97B	0	1.9B	3.24B	130M	816M	513M	464M	912M
Accounts Receivable	6.3B	5.75B	7.68B	10.3B	12.52B	13.94B	15.26B	11.13B	14.53B	9.37B
Days Sales Outstanding	110.68	92.98	107.29	88.42	98.49	110.21	123.79	84.12	110.01	100.9
Inventory	1.17B	1.2B	4.29B	2.07B	2.1B	2.34B	2.66B	2.56B	2.69B	2.76B
Days Inventory Outstanding	70.16	66.62	193.98	64.3	76.93	84.22	90.87	44.72	59.74	47.07
Other Current Assets	0	1.12B	5.03B	1.28B	1.43B	1.74B	1.56B	1.94B	1.5B	4.6B
Total Non-Current Assets	18.7B	1.77B	100.59B	88.29B	76.05B	69.55B	63.39B	62.82B	60.65B	59.27B
Property, Plant & Equipment	5B	5.03B	6.25B	6.75B	6.97B	7.47B	8.04B	8.36B	9.13B	7.66B
Fixed Asset Turnover	4.15x	4.49x	4.18x	6.30x	6.66x	6.18x	5.60x	5.78x	5.28x	7.68x
Goodwill	6.86B	6.54B	22.49B	20.55B	20.5B	21.15B	21.17B	21.72B	21.75B	21.74B
Intangible Assets	1.21B	1.09B	63.97B	53.24B	42.77B	36.35B	27.07B	23.31B	19.1B	18.24B
Long-Term Investments	2.48B	1.77B	767M	4.85B	2.71B	2.19B	2.5B	2.51B	2.51B	7.12B
Other Non-Current Assets	1.53B	-14.03B	6.6B	1.75B	1.66B	1.04B	1.84B	2.69B	2.78B	29.26B
Total Assets	33.55B▲ 0%	10.66B▼ 68.2%	129.94B▲ 1119.1%	118.48B▼ 8.8%	109.31B▼ 7.7%	96.82B▼ 11.4%	95.16B▼ 1.7%	92.6B▼ 2.7%	90.04B▼ 2.8%	86.48B▲ 0%
Asset Turnover	0.62x	2.12x	0.20x	0.36x	0.42x	0.48x	0.47x	0.52x	0.54x	0.53x
Asset Growth %	-0.46%	-68.23%	1119.1%	-8.82%	-7.74%	-11.43%	-1.72%	-2.69%	-2.77%	-5.74%
Total Current Liabilities	9.56B	1.7B	18.3B	19.08B	21.87B	21.89B	22.26B	23.77B	23.42B	19.16B
Accounts Payable	2.25B	1.89B	2.44B	2.71B	2.95B	3.04B	3.26B	3.6B	3.58B	4.23B
Days Payables Outstanding	135.27	105.48	110.48	84.11	108.29	109.46	111.24	63	79.39	99.96
Short-Term Debt	987M	1.7B	3.35B	2.5B	4.95B	4.26B	3.12B	2.05B	2.46B	2.31B
Deferred Revenue (Current)	83M	172M	4.49B	0	3.69B	1.34B	4.22B	0	0	0
Other Current Liabilities	5.11B	5.61B	-79M	11.8B	174M	2.87B	456M	15.17B	14.84B	12.62B
Current Ratio	1.55x	5.22x	1.60x	1.58x	1.52x	1.25x	1.43x	1.25x	1.26x	1.26x
Quick Ratio	1.43x	4.51x	1.37x	1.47x	1.43x	1.14x	1.31x	1.15x	1.14x	1.14x
Cash Conversion Cycle	45.58	54.12	190.79	68.61	67.13	84.97	103.41	65.85	90.36	48.01
Total Non-Current Liabilities	12.14B	5.65B	59.94B	61.52B	51.44B	43.81B	43.41B	52.44B	48.12B	47.22B
Long-Term Debt	6.97B	5.65B	43.39B	48.34B	39.6B	35.06B	36.65B	47.6B	44.68B	42.15B
Capital Lease Obligations	0	0	672M	833M	874M	1.26B	1.53B	1.37B	1.83B	5.22B
Deferred Tax Liabilities	0	-4.56B	6.45B	5.41B	4.5B	2.17B	338M	369M	222M	905M
Other Non-Current Liabilities	4.71B	4.09B	9.01B	6.59B	6.13B	5.05B	4.59B	2.87B	1.22B	12.7B
Total Liabilities	21.7B	7.35B	78.25B	80.6B	73.31B	65.7B	65.67B	76.22B	71.53B	66.37B
Total Debt	7.96B	7.35B	47.54B	51.67B	45.6B	40.72B	41.46B	51.2B	48.97B	44.46B
Net Debt	2.54B	438M	35.19B	37.04B	31.62B	31.59B	30B	40.85B	38.76B	34.89B
Debt / Equity	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x	2.65x	2.65x
Debt / EBITDA	1.84x	1.26x	6.21x	4.12x	2.37x	2.10x	2.31x	2.66x	2.55x	2.41x
Net Debt / EBITDA	0.59x	0.08x	4.59x	2.95x	1.64x	1.63x	1.67x	2.12x	2.01x	2.01x
Interest Coverage	27.18x	33.61x	8.58x	-3.84x	7.07x	7.26x	8.24x	-3.30x	7.99x	8.50x
Total Equity	11.85B▲ 0%	14.13B▲ 19.2%	51.7B▲ 266.0%	37.88B▼ 26.7%	36.01B▼ 5.0%	31.12B▼ 13.6%	29.48B▼ 5.2%	16.39B▼ 44.4%	18.51B▲ 12.9%	20.1B▲ 0%
Equity Growth %	-27.53%	19.25%	265.95%	-26.72%	-4.95%	-13.58%	-5.25%	-44.42%	12.92%	38.74%
Book Value per Share	7.17	8.63	30.20	16.78	16.04	14.50	14.19	8.08	9.08	9.82
Total Shareholders' Equity	11.74B	14.03B	51.6B	37.82B	35.95B	31.06B	29.43B	16.34B	18.47B	20.07B
Common Stock	221M	221M	292M	292M	292M	292M	292M	292M	292M	292M
Retained Earnings	31.16B	34.06B	34.47B	21.28B	23.82B	25.5B	28.77B	14.91B	16.9B	18.29B
Treasury Stock	-19.25B	-19.57B	-25.36B	-26.24B	-31.26B	-38.62B	-43.77B	-43.66B	-43.58B	0
Accumulated OCI	-2.29B	-2.76B	-1.52B	-1.84B	-1.27B	-1.28B	-1.55B	-1.24B	-1.52B	-1.37B
Minority Interest	106M	96M	100M	60M	60M	57M	55M	53M	33M	34M

CELG-RI Cash Flow Statement

Bristol-Myers Squibb Company Ce (CELG-RI) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	5.28B	5.94B	8.07B	14.05B	16.21B	13.07B	13.86B	15.19B	14.16B	14.16B
Operating CF Margin %	25.39%	26.33%	30.85%	33.05%	34.94%	28.31%	30.8%	31.45%	29.37%	-
Operating CF Growth %	85.09%	12.61%	35.81%	74.19%	15.34%	-19.38%	6.08%	9.6%	-6.81%	-17.75%
Net Income	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B	7.05B	7.28B
Depreciation & Amortization	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B	4.12B	3.65B
Stock-Based Compensation	199M	221M	441M	779M	583M	457M	518M	507M	0	422M
Deferred Taxes	1.01B	86M	-924M	983M	-1.39B	-2.74B	-3.29B	-2.09B	-965M	-1.03B
Other Non-Cash Items	714M	-127M	279M	9.92B	570M	955M	744M	15.29B	4.4B	1.57B
Working Capital Changes	1.59B	176M	3.06B	983M	-1.25B	-2.23B	-1.91B	810M	-455M	1.42B
Change in Receivables	-431M	-267M	1.66B	-2.95B	-2.12B	-663M	-995M	264M	-295M	1.38B
Change in Inventory	-29M	-216M	463M	2.67B	13M	-69M	-751M	-486M	-184M	-1M
Change in Payables	320M	-59M	229M	188M	245M	109M	198M	184M	-2M	492M
Cash from Investing	-66M	-874M	-9.77B	-10.86B	-538M	-1.06B	-2.29B	-21.35B	-4.13B	-3.76B
Capital Expenditures	-1.05B	-951M	-836M	-753M	-973M	-1.12B	-1.21B	-1.25B	-1.31B	-1.4B
CapEx % of Revenue	5.08%	4.22%	3.2%	1.77%	2.1%	2.42%	2.69%	2.58%	2.72%	-
Acquisitions	14M	3M	-8.78B	-12.21B	-862M	-2.98B	-260M	-21.82B	-2.87B	-4.17B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.72B	1.32B	0	0	0	0	0	1.1B	0	1.37B
Cash from Financing	-4.08B	-3.54B	7.62B	-1.15B	-16.22B	-16.96B	-9.42B	5.13B	-10.35B	-10.91B
Debt Issued (Net)	991M	-548M	17.65B	3.93B	-6.18B	-5.31B	456M	10.1B	-5.17B	-5.54B
Equity Issued (Net)	-2.47B	-320M	-7.3B	-1.55B	-6.29B	-8B	-5.16B	0	0	0
Dividends Paid	-2.58B	-2.61B	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B	-4.86B	-5.04B	-5.07B
Share Repurchases	-2.47B	-320M	-7.3B	-1.55B	-6.29B	-8B	-5.16B	0	0	0
Other Financing	-22M	-54M	-53M	542M	641M	984M	27M	-106M	-128M	-302M
Net Change in Cash	1.18B▲ 0%	1.49B▲ 25.8%	5.91B▲ 296.6%	2.15B▼ 63.6%	-657M▼ 130.5%	-4.99B▼ 659.7%	2.19B▲ 144.0%	-1.17B▼ 153.4%	-137M▲ 88.3%	-1.3B▲ 0%
Free Cash Flow	4.22B▲ 0%	4.99B▲ 18.2%	7.23B▲ 44.9%	13.3B▲ 83.9%	15.23B▲ 14.5%	11.95B▼ 21.6%	12.65B▲ 5.9%	13.94B▲ 10.2%	12.85B▼ 7.9%	11.91B▲ 0%
FCF Margin %	20.31%	22.11%	27.66%	31.28%	32.84%	25.88%	28.11%	28.87%	26.65%	24.56%
FCF Growth %	158.1%	18.22%	44.94%	83.92%	14.55%	-21.57%	5.88%	10.2%	-7.87%	-9%
FCF per Share	2.55	3.05	4.22	5.89	6.79	5.57	6.09	6.88	6.30	6.30
FCF Conversion (FCF/Net Income)	5.24x	1.20x	2.35x	-1.56x	2.32x	2.07x	1.73x	-1.70x	2.01x	1.64x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

CELG-RI Key Ratios

Bristol-Myers Squibb Company Ce (CELG-RI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.14%	38.13%	10.45%	-20.13%	18.93%	18.85%	26.48%	-39.01%	40.43%	38.96%
Return on Invested Capital (ROIC)	15.58%	26.52%	8.74%	2.02%	8.98%	10.48%	10.06%	12.41%	19.8%	19.8%
Gross Margin	70.8%	70.98%	69.1%	72.31%	78.57%	78.04%	76.24%	56.79%	65.9%	67%
Net Margin	4.85%	21.95%	13.15%	-21.2%	15.08%	13.71%	17.83%	-18.53%	14.64%	15.01%
Debt / Equity	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x	2.65x	2.65x
Interest Coverage	27.18x	33.61x	8.58x	-3.84x	7.07x	7.26x	8.24x	-3.30x	7.99x	8.50x
FCF Conversion	5.24x	1.20x	2.35x	-1.56x	2.32x	2.07x	1.73x	-1.70x	2.01x	1.64x
Revenue Growth	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%	-0.22%	1.78%

CELG-RI SEC Filings & Documents

Bristol-Myers Squibb Company Ce (CELG-RI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Feb 5, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 12, 2025·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 30, 2025·SEC

FY 2025

Jul 31, 2025·SEC

CELG-RI Frequently Asked Questions

Bristol-Myers Squibb Company Ce (CELG-RI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Bristol-Myers Squibb Company Ce (CELG-RI) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.

Bristol-Myers Squibb Company Ce (CELG-RI) saw revenue decline by 0.2% over the past year.

Yes, Bristol-Myers Squibb Company Ce (CELG-RI) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).

Dividend & Returns

Yes, Bristol-Myers Squibb Company Ce (CELG-RI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Bristol-Myers Squibb Company Ce (CELG-RI) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.

Bristol-Myers Squibb Company Ce (CELG-RI) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CELG-RI

Bristol-Myers Squibb Company Ce (CELG-RI) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Bristol-Myers Squibb Company Ce(CELG-RI)Earnings, Financials & Key Ratios

CELG-RI Key Insights

✓Strengths

✗Weaknesses

CELG-RI Price & Volume

CELG-RI Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CELG-RI Recent Earnings

CELG-RI Peer Comparison

Compare CELG-RI vs Peers

vs BMY

vs LLY

Compare Top 5

CELG-RI Income Statement

CELG-RI Balance Sheet

CELG-RI Cash Flow Statement

CELG-RI Key Ratios

CELG-RI SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

CELG-RI Frequently Asked Questions

Explore More CELG-RI

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation